Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago
Probiodrug announces pricing of a EUR 13.5 million private placement of new shares
Probiodrug presented data on its pGlu-3 Abeta monoclonal Antibody at Neuroscience 2015, Chicago
Probiodrug announces pricing of a EUR 13.5 million private placement of new shares
HALLE/SAALE, Germany, 28 October 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is scheduled to attend and present at the following conferences:
(1) BIO-Europe 2015
2-4 November 2015, International Congress Center, Munich, Germany
Dr Konrad Glund, CEO, to present on 4 November at 10:00 CET in Room 12, Level 1
BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. The conference attracts leading dealmakers from biotech, pharma and finance along with exciting emerging companies. BIO-Europe is regarded as a “must attend” event for the biotech industry.
(2) CTAD
5-7 November 2015, Gran Hotel Princesa Sofia, Barcelona, Spain
Dr Konrad Glund, CEO, Dr Inge Lues, CDO and Dr Frank Weber, CMO, will be attending the conference
The 8th Annual International Conference on Clinical Trials for Alzheimer’s Disease (CTAD) will gather more than 800 global researchers to review the most important and promising developments in the field. Clinical trial teams from around the world will report on their efforts to identify new biomarkers, discover more sensitive tools to identify those at risk for the disease and assess the effectiveness of new treatments. This year’s meeting will feature over 70 oral presentations and more than 200 poster sessions on Phase 2 and 3 clinical trials, prevention studies and animal models.
(3) Jefferies 2015 Global Healthcare Conference
18-19 November 2015, The May Fair Hotel, London, UK
Dr Hendrik Liebers, CFO, will be attending and hosting meetings at the conference
The two-day event will include company presentations, thematic panel discussions, 1×1 investor meetings and, as a continuing unique feature, business-to-business meetings that offer an excellent opportunity for companies to get introduced to or refresh the dialogue with senior executives and owners.
This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.
23-25 November, Sheraton Airport Hotel and Conference Center, Frankfurt/Main, Germany
Dr Hendrik Liebers, CFO, to present on 23 November at 17:00 CET in Room Oslo
With thousands of participants from the financial community, entrepreneurs, investors and analysts, the event establishes an international network and information platform across Europe. As one of the world´s largest exchange organisations, Deutsche Börse AG and the KfW, a leading development bank, provide an optimal platform to promote greater engagement between capital seeking companies and investors.
For more information, please contact:
Probiodrug
Dr Konrad Glund, CEO
Email: contact@probiodrug.de
Hume Brophy
Mary Clark, Supriya Mathur, Alexia Faure
Tel: +44 (0) 203 440 5657
Email: probiodrug@humebrophy.com
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext Amsterdam: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s disease treatments and to thereby provide a better life for Alzheimer’s disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.
About Alzheimer’s disease
Alzheimer’s disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 44 million people worldwide currently live with the condition and this number is expected to almost double by 2030 and to more than triple by 2050 to over 132 million. Alzheimer’s also has an estimated, global societal cost of over $600 billion (World Alzheimer Report 2014).
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.